Trial finds Zanidatamab + chemo beneficial in HER2-positive gastroesophageal cancer

For patients with human epidermal growth factor receptor 2-positive (HER2-positive) metastatic or locally advanced unresected gastroesophageal adenocarcinoma (mGEA), zanidatamab and chemotherapy, with or without tislelizumab, may prolong survival…

Continue Reading

News Source: medicalxpress.com